Vir Biotechnology’s Sotrovimab Receives NICE Recommendation for COVID-19

Share this
Vir Biotechnology’s

Vir Biotechnology’s Sotrovimab Receives NICE Recommendation for COVID-19


  • NICE issued a positive final draft guidance recommending the use of sotrovimab, a SARS-CoV-2 neutralizing mAb in adults who do not need supplemental oxygen for COVID-19 & have an increased risk for progression to sev. COVID-19
  • In Mar 2023, NICE is anticipated to release its final COVID-19 treatment recommendations. Sotrovimab has obtained emergency authorization, temporary authorization, or marketing approval (under the brand name Xevudy) for COVID-19. It is now available in 40+ countries & is not authorized in the US
  • With the help of Xencor’s Xtend technology, sotrovimab has also been developed to achieve high concentrations in the lungs for optimal penetration into SARS-CoV-2-affected airway tissues & to have a long half-life

Ref: GlobeNewswire | Image: Vir Biotechnology

Related Post:- Vir Biotechnology Reports the First Patient Dosing in the P-II (SOLSTICE) Trial of VIR-2218 and VIR-3434 for Chronic Hepatitis D Virus Infection

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions